Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D.
Harbeck N, et al. Among authors: wrobel d.
Breast Care (Basel). 2024 Feb;19(1):1-9. doi: 10.1159/000533657. Epub 2023 Oct 5.
Breast Care (Basel). 2024.
PMID: 38384488
Free article.